- Autoimmune Disorders in Women Possibly Triggered by Seafood
- FDA Approves Noninvasive Colorrectal Cancer Test
- FDA Approves Limited Use of Drug for Ebola
- FDA Approves Edwards Lifesciences Corporation’s Sapien XT
- Lymphoseek Injections Approved by FDA for Prolonged Extended Use
- Orexigen Therapeutics’ Contrave Awaits FDA’s Nod
- FDA Expressed Concern on E-Cigarette Smoking after Increase in Complaint Rate
- E-Cigarette Marketing to Be Regulated by FDA Appealed As They Pose Serious Threat to the Youth
- FDA Goes Tough on Honey with Added Sweeteners
- Is Your Honey Adulterated?
Risk of Blood Clots Reduced with Low-Dose Aspirin
- Updated: August 26, 2014
Medical professionals have recommended the use of aspirin to lower risk of heart attack for decades but in a new study, promising news reveals that aspirin can also lower the risk of blood clots. Researchers in Australia completed this new study, finding the occurrence of new venous blood clots can be treated with low-dose aspirin.
Not only does aspirin help to reduce risk of developing a blood clot, the study found it is beneficial to people who have already had one or more blood clots. As such, it appears that low-dose aspirin is an excellent treatment options for patients who are not good candidates for warfarin, as well as other long-term anticoagulant medications.
According to the study’s lead author and professor at the University of Sydney, John Simes, aspirin is a beneficial treatment in lieu of long-term anticoagulants, which is costly but also presents increased risk of bleeding.
As part of the Australian study, one group of participants was given aspirin compared to the other group who was given a placebo. The group who took 100 milligrams of aspirin daily had a 33% reduction in risk of thromboemebolism, which is an obstruction of a blood vessel caused by a blood clot. However, that same group also had a 33% reduction in risk for Deep Vein Thrombosis (DVT), which involves the formation of a blood clot in a deep vein, most commonly in the legs.
Another discovery associated with this study was that pulmonary embolism, a blood clot that affects the arteries supplying blood to the lungs, was also lowered. Typically, treatment using warfarin or another type of long-term anticoagulant lasts a minimum of six months for an embolism, involving clots that stop blood flow, as well as a deep vein clot.
Again, treatment of this type has downfalls, again being expensive and risky for bleeding. In comparison, people who cannot take the long-term medication have new hope with aspirin. Simes continue by stating that not only is aspirin a tremendous benefit from a medical standpoint, it is a much more cost-effective solution.